Novozymes A/S produces and sells industrial enzymes and microorganisms worldwide. It operates in three divisions: Household Care & Technical, Agriculture & Bioenergy, and Food & Beverages. The company offers enzymes for use in household care products, such as laundry detergents, hand and automatic dishwashing soaps, and professional cleaning products. It also provides enzymes for baking applications, including freshness, product appearance, dough improvement, etc.; and brewing applications comprising fermentation control, separation and filtration, etc., as well as for use in lactose-free dairy, trans fats removal, etc. in the food and beverages industry. In addition, the company offers enzymes and microorganisms for use in the production of cellulosic ethanol, starch-based ethanol, enzymatic biodiesel, and sugarcane ethanol in the bioenergy industry; and feed enzymes for use in animal feed, probiotics for animal health applications, microbials for aquaculture applications, and other enzymes and microorganisms for plant health and crop yield applications in the agriculture and feed industry. Further, it provides enzymes and microorganisms for use in textile processing, pulp and paper production, leather preparation, pharmaceuticals, and wastewater treatment solutions. The company has a strategic collaboration with Boehringer Ingelheim Animal Health for research and development, production, marketing, and sale of a portfolio of probiotic products. It also has a collaboration agreement with Elanco Animal Health Incorporated. Novozymes A/S was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorBasic Materials
Phone45-4446-0000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.21 billion
Profitability
Miscellaneous
Employees6,245
OptionableNot Optionable
NOVOZYMES A/S/S (OTCMKTS:NVZMY) Frequently Asked Questions
What is NOVOZYMES A/S/S's stock symbol?
NOVOZYMES A/S/S trades on the OTCMKTS under the ticker symbol "NVZMY."
How were NOVOZYMES A/S/S's earnings last quarter?
NOVOZYMES A/S/S (OTCMKTS:NVZMY) announced its quarterly earnings data on Wednesday, October, 24th. The biotechnology company reported $0.43 earnings per share for the quarter. The biotechnology company had revenue of $570.42 million for the quarter. NOVOZYMES A/S/S had a return on equity of 29.84% and a net margin of 22.20%. View NOVOZYMES A/S/S's Earnings History.
When is NOVOZYMES A/S/S's next earnings date?
What is the consensus analysts' recommendation for NOVOZYMES A/S/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NOVOZYMES A/S/S in the last year. There are currently 1 sell rating for the stock, resulting in a consensus recommendation of "Sell." View Analyst Ratings for NOVOZYMES A/S/S.
Has NOVOZYMES A/S/S been receiving favorable news coverage?
Media headlines about NVZMY stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. NOVOZYMES A/S/S earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
Who are some of NOVOZYMES A/S/S's key competitors?
Some companies that are related to NOVOZYMES A/S/S include Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI) and Crispr Therapeutics (CRSP).
Who are NOVOZYMES A/S/S's key executives?
NOVOZYMES A/S/S's management team includes the folowing people:
- Mr. Peder Holk Nielsen, Pres & CEO (Age 62)
- Mr. Thomas Videbaek, Exectuive VP & COO of Research, Innovation & Supply (Age 58)
- Mr. Andrew Fordyce, Exec. VP of Food & Beverages (Age 55)
- Mr. Per Falholt, Consultant (Age 60)
- Dr. Prisca Havranek-Kosicek, CFO & Exec. VP of Corp. Functions (Age 43)
How do I buy shares of NOVOZYMES A/S/S?
Shares of NVZMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is NOVOZYMES A/S/S's stock price today?
One share of NVZMY stock can currently be purchased for approximately $45.63.
How big of a company is NOVOZYMES A/S/S?
NOVOZYMES A/S/S has a market capitalization of $13.31 billion and generates $2.21 billion in revenue each year. The biotechnology company earns $473.62 million in net income (profit) each year or $1.59 on an earnings per share basis. NOVOZYMES A/S/S employs 6,245 workers across the globe.
What is NOVOZYMES A/S/S's official website?
How can I contact NOVOZYMES A/S/S?
NOVOZYMES A/S/S's mailing address is Krogshoejvej 36, Bagsvaerd G7, 2880. The biotechnology company can be reached via phone at 45-4446-0000 or via email at [email protected]
MarketBeat Community Rating for NOVOZYMES A/S/S (OTCMKTS NVZMY)
MarketBeat's community ratings are surveys of what our community members think about NOVOZYMES A/S/S and other stocks. Vote "Outperform" if you believe NVZMY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVZMY will underperform the S&P 500 over the long term. You may vote once every thirty days.
